Avoid common mistakes on your manuscript.
Correction: Rheumatol Ther (2023) 10:1055–1072 https://doi.org/10.1007/s40744-023-00568-8
The original article was published with four wrong Supplementary files; these have now been replaced with the correct one file.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Curtis, J.R., Yun, H., Chen, L. et al. Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry. Rheumatol Ther 11, 217 (2024). https://doi.org/10.1007/s40744-023-00607-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-023-00607-4